Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT00885547 Terminated - IgA Nephropathy Clinical Trials

Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

Start date: March 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.

NCT ID: NCT00856674 Terminated - Proteinuria Clinical Trials

Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy

Start date: March 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of several dose levels of CCL2-LPM in patients with IgA Nephropathy who have high levels of protein in the urine.

NCT ID: NCT00318474 Terminated - IgA Nephropathy Clinical Trials

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

Start date: January 2002
Phase: Phase 3
Study type: Interventional

IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal disease (ESRD). The study is to evaluate the safety and benefits of MMF in patients with IgAN who have been pre-treated (and continue to be treated) with angiotensin converting enzyme inhibitors (ACEi) and fish oil supplements (FOS).